Who's buying wellness
and supplement
brands in 2026.

Ask any supplement founder what a business like theirs is worth, and they reach for the same handful of 2026 headlines. Unilever paid roughly $1.2 billion for Grüns, a greens gummy brand barely two years old. Prestige paid more than a billion for Breathe Right nasal strips. L Catterton put Thorne on the market with an ask near $4 billion. Then they look at their own reorder rate and their own margin and ask the only question that matters: what would a buyer actually pay for this, and what makes that number move?

The honest read is narrower than those three headlines suggest. Wellness and supplement brands trade at a genuine premium to the broad consumer market, and the reason is boring and durable: people finish a bottle and buy another one. That replenishment turns into subscription and repeat revenue a buyer can underwrite, which is why the sector cleared about 10.7x EV to EBITDA across 2024 to mid-2025, versus roughly 9.7x for consumer overall, per Capstone Partners' vitamins and supplements coverage. The disclosed 2026 deals sat right on top of that: Prestige paid 11.0x EBITDA for Breathe Right, and Essity paid 12.1x for a feminine-care portfolio. The premium is real, but it attaches to specific things, and the gap between the headline deals and the median brand is wider than founders assume.

I've sat on the side of the table that sets these numbers. At WIN Brands Group we built consumer brands and we bought brands to fold into the portfolio, which means I've run the quality-of-earnings work that takes a founder's reported numbers apart line by line. In wellness there is an extra line most other categories don't have: the claims and regulatory review, where a buyer prices the risk that a marketing claim or a supplier shortcut turns into a liability after close. That review moves the multiple as much as the growth rate does.

This is the reference version. The full 2026 deal ledger, the multiples that actually applied, the four buyer camps and how each one prices you, why Unilever is quietly building the category's dominant platform, why supplements price differently than beauty, the venture money that predicts the next M&A wave, and what makes a wellness brand worth a premium in the first place. If you're building toward a sale, this is the math that decides the outcome.

One caveat before we start. Every figure here is grounded in a real, reported deal or a published benchmark, and each source is named in the text. Where a price is reported but not officially disclosed, I say so. Implied multiples are approximations, because enterprise value and revenue timing are rarely published cleanly. Treat the ranges as the shape of the market, not a quote on your brand.

The 2026 wellness and
supplement deal
ledger.

The first half of 2026 produced a dense run of wellness and supplement transactions, and three of them cleared a billion dollars in headline or ask. Unilever agreed to buy Grüns for about $1.2 billion in April and closed on June 1, per Unilever's release and reporting from Forbes and Axios. Prestige Consumer Healthcare agreed to buy Breathe Right and a set of related OTC brands for $1.045 billion in March, closing in mid-June, per Prestige's SEC filing. And L Catterton kicked off a sale of Thorne at up to $4 billion, drawing reported interest from Unilever and Haleon, per the Financial Times via Axios.

Those are the anchors. Underneath them sits a longer list of disclosed and reported deals across supplements, OTC wellness, self-care, and adjacent categories. The table below is the ledger, newest anchors first, with the buyer, the price where it was reported, and the multiple or note where one exists.

A few patterns jump out of the ledger. The billion-dollar deals went to category leaders with real scale: a nasal-strip franchise doing roughly $200 million in revenue, a greens brand with more than a million customers, a supplement house on track for $650 million. The mid-market deals, the wellness shots, the antacids, the insoles, mostly went undisclosed, which is normal, because the quiet transactions in the middle of the distribution rarely publish a price. And the buyer names repeat: Unilever, Prestige, a cluster of private equity platforms, and public strategics buying an adjacent line. This is a category being consolidated by a small set of repeat acquirers, which is exactly the same dynamic reshaping the broader consumer M&A window that reopened in 2026.

Sports nutrition deserves its own line, because Nutrabolt is taking a different exit door. Rather than sell, the maker of C4, XTEND, and Cellucor picked JPMorgan, Goldman Sachs, and Bank of America to lead a US IPO that could raise up to $1 billion, per Reuters, on a business tracking above $1 billion in consolidated revenue. Keurig Dr Pepper bought 30% of it in 2022 at a $2.88 billion valuation, so a public listing is the natural next step. When a category leader can credibly IPO, it raises the floor for everyone else's private sale, because a public alternative gives the seller leverage.

What wellness and
supplement brands
sell for.

The vitamins, minerals, and supplements sector averaged about 10.7x EV to EBITDA across 2024 to mid-2025, above the roughly 9.7x for the broader consumer industry, per Capstone Partners. That is your anchor for a healthy, profitable supplement brand sold to a buyer running EBITDA math. The disclosed 2026 leaders landed right there or above: Prestige paid 11.0x EBITDA for Breathe Right, and Essity paid 12.1x EBITDA for Edgewell's feminine-care portfolio. Category leadership plus durable cash flow is what earns the double-digit number.

But an average hides a wide spread, and which multiple a buyer reaches for tells you how they see the brand. A fast-growing brand gets priced on revenue instead of EBITDA, because the buyer is paying for a curve rather than current profit. Unilever's roughly $1.2 billion for Grüns is a revenue conversation: the brand is barely two years old, so there isn't a long profit history to underwrite, only a steep growth line and a category thesis. Thorne's up-to-$4-billion ask against roughly $650 million of revenue works the same way, near 6x sales, justified by compounded growth above 30% since L Catterton took it private at about $680 million in 2023.

Founders fall into one trap here. A supplement brand doing $15 million at a 12% EBITDA margin dreams of the 4x-sales number it read about, which would be $60 million. But if growth has cooled and a financial sponsor is the realistic buyer, the conversation is 5x EBITDA on about $1.8 million of profit, which is closer to $9 million. The gap between those two numbers is enormous, and it comes down entirely to which multiple gets applied. The revenue multiple only attaches to a genuinely fast-growing, scarce brand. For everyone else, EBITDA is the conversation, and that is the same discipline that decides the EBITDA line that makes a brand sellable.

Read the headline numbers carefully, too, because a chunk of a celebrated price is often money you have to go earn. Deals like It Works! into Zinzino carry an earnout, cash at close plus more if the brand hits targets. That structure is how a buyer bridges the gap between what a founder believes and what the buyer will commit to today. For a fuller picture of how these ranges compare across categories, the companion breakdown of consumer brand multiples by category lays the sectors side by side.

The four camps buying
wellness, and how each
one prices you.

The 2026 buyer pool splits into four camps, and the camp that buys you shapes your multiple more than almost anything about the brand. The same $30 million supplement brand can be worth 5x EBITDA to one buyer and a revenue premium to another, because they underwrite different things. Knowing which camp you're built for is the difference between running the right process and the wrong one.

The first camp is the consumer strategics building a wellbeing arm, and they write the biggest checks. Unilever is the clearest example, with Grüns, Nutrafol, Olly, SmartyPants, and Liquid I.V. already inside a dedicated Wellbeing unit, and a reported bid in for Thorne. Procter & Gamble bought Wonderbelly to modernize its OTC shelf. These buyers pay up when a brand fills a portfolio gap and reaches a consumer they've aged out of, because they can underwrite distribution and manufacturing a spreadsheet can't capture.

The second camp is the consumer-health and OTC specialists, and they are the disciplined check-writers. Prestige Consumer Healthcare buys durable, cash-generating OTC brands and paid a clean 11.0x EBITDA for Breathe Right. Haleon, the consumer-health company spun out of GSK, joined the Thorne process. These buyers know the regulatory terrain cold, so they don't flinch at the claims-and-compliance line the way a non-specialist buyer might, but they also won't overpay for a momentum story. They price on defensible cash flow.

The third camp is private equity platforms and sponsors, and they set the floor. L Catterton is the category's most active sponsor, seller of Thorne and backer of a string of wellness brands. Bansk Group took a majority stake in So Good So You as Prelude Growth exited. Yellow Wood Partners owns Dr. Scholl's, which picked up VKTRY. These buyers underwrite EBITDA and free cash flow, not the distribution a strategic already owns, so their headline multiple is usually lower than a strategic's, but the structure can be better: rollover equity and a second bite when the platform sells to a strategic later. The institutions doing this work are the same ones mapped in the rundown of the institutional acquirers rolling up consumer brands.

The fourth camp is the adjacent public strategics and direct-sellers, and they are the wildcard that widens your buyer pool. Essity, a hygiene major, bought Edgewell's feminine-care line. Laird Superfood, a public brand, added Terrasoul. Zinzino, a direct-selling company, merged with It Works!. Country Life bought Aura Cacia. None of these is an obvious wellness acquirer, which is exactly why they matter: an unexpected bidder is what turns a quiet process into a real auction, and competitive tension is what actually moves a price.

Unilever is quietly
building the category's
dominant platform.

If you want to understand where wellness M&A is heading, watch Unilever. Its Wellbeing arm already holds Liquid I.V., Nutrafol, Olly, and SmartyPants, and in 2026 it added Grüns for about $1.2 billion and put in a reported bid for Thorne at up to $4 billion. No other buyer is assembling a supplement and wellness platform this deliberately, and a repeat acquirer with a clear thesis changes the math for every founder in the category.

The logic is the one strategics always run: it's cheaper and faster to buy proven growth than to build it. Unilever has the distribution, the manufacturing, and the retail relationships, but it can't manufacture the cultural pull of a greens gummy that reached a million customers in under three years, so it buys one. Grüns closed on June 1 and slotted straight into the Wellbeing unit. Thorne, if Unilever wins it, would add a clinical, practitioner-trusted supplement house at the top end of the category. Together they'd give one company positions in greens, hair wellness, kids' vitamins, hydration, and clinical supplements.

For a founder, a repeat buyer with a stated appetite is both an opportunity and a warning. The opportunity is a clear, motivated acquirer you can build toward: if your brand plausibly fills a gap in the Wellbeing portfolio, you have a credible premium buyer in mind years before a process. The warning is that these buyers get more selective as the platform fills in. Once a strategic owns the greens slot and the hair-wellness slot, it stops paying up for a second one. Timing your process to when a specific buyer's portfolio still has your gap open is worth real money.

I watched this play out from the buy side more than once. The brands that drew genuine competitive tension weren't always the biggest or fastest growing. They were the ones that were obviously the missing piece in a specific acquirer's portfolio, the position a strategic would rather buy than spend three years trying to build. When two strategics both see you as that piece, the multiple takes care of itself. When nobody does, you're negotiating against a discounted-cash-flow model, and that's a colder room.

Why supplements price
differently than
beauty.

Supplements and beauty both clear premiums, but for different reasons, and the difference matters when you're building toward a sale. Beauty's premium comes from gross margin, roughly a 69% median across public beauty, which funds heavy marketing. Supplements earn their premium from replenishment: the product gets consumed and rebought on a cycle, so a healthy brand carries subscription and repeat revenue that reads as durable to a buyer. A capsule or a gummy is a habit, and habits are worth more per dollar of profit than a one-time purchase.

That replenishment is why so many supplement brands run on subscription, and why a buyer digs hard into the retention curve rather than the last quarter's new-customer number. A brand that acquires well but leaks subscribers is buying its growth over and over, and a buyer prices that fragility in. A brand with a durable reorder rate is a flywheel, and it commands the durable multiple. This is the same retention math that governs subscription churn and replenishment retention across DTC, and it's the single number I'd protect above all others in this category.

Then there's the line no beauty brand carries the same way: regulatory and claims risk. Supplements sit under the FDA's dietary-supplement framework and the FTC's rules on health claims. A buyer's diligence team reads every product claim, every ingredient sourcing arrangement, and every piece of marketing copy, pricing the risk that a claim invites a warning letter or a class action after close. A brand that markets aggressive efficacy it can't substantiate is worth less than a slightly slower brand with clean, defensible claims, because the buyer is inheriting the liability. In beauty that risk exists; in supplements it's front and center.

Margin still matters, but its shape is different. Supplement gross margins are healthy, though usually below prestige beauty, and a buyer cares more about whether the margin survives a switch from a contract manufacturer to a scaled supply chain, and whether it depends on a single hero SKU. The strongest supplement brands look like the strongest brands in any category on the fundamentals, which is why the category-specific unit economics are worth mapping honestly before you market the business. The premium is earned in the numbers, not asserted in the deck.

The venture money
flooding wellness
in 2026.

The 2026 funding rounds are a preview of the 2027 and 2028 acquisition targets, and the money is pouring in. In the first half of 2026, wellness and supplement brands raised across gut health, adaptogens, peptides, hormone health, and women's health, the exact adjacencies the strategics are chasing. Nourish, a nutrition-counseling company, raised $100 million at a $1.75 billion valuation. WHOOP raised $575 million at a $10.1 billion valuation on a roughly $1.1 billion revenue run rate. When the venture pipeline funds a theme, the strategics come shopping in it a year or two later.

Two signals in that table are worth calling out. First, Unilever Ventures led a round in Supply6, an Indian supplement company, which is the strategic scouting future targets through its venture arm. When a corporate venture fund backs an emerging brand, it's building an option to acquire. Second, L Catterton, the sponsor selling Thorne, also led the hormone brand Mars, which is how a platform sponsor keeps a pipeline of the next thing while it exits the last one.

The themes are as informative as the dollars. Peptides showed up twice (Protocole and Feel Peptides), gut health and women's health each drew institutional leads, and creatine went mainstream enough for a gummy brand to raise on a 320% jump. If you're operating a brand in one of these lanes, the venture money is validating your category and, indirectly, funding the competitors a strategic might buy instead of you. That's a reason to build for durability now, not later.

What makes a wellness
brand worth a premium
multiple.

Beyond the deal math, a buyer is asking a simpler question: is this a brand I'd want to own and run? Five things answer it, and they're the same five whether the buyer is a strategic, a sponsor, or an OTC specialist. A brand strong on all five draws a competitive process. A brand weak on two of them gets one interested buyer and a take-it-or-leave-it offer, no matter how good the last quarter looked.

One: replenishment you can prove. This is the category's foundation. A supplement is a habit, so the reorder rate and the subscription curve are the numbers a buyer trusts most. Show durable repeat behavior in the cohort data, not just a strong new-customer number, and you're telling a durability story a buyer will pay the double-digit EBITDA multiple for. A leaky subscriber base caps the multiple even when acquisition looks great.

Two: clean claims and regulatory hygiene. This is the supplement-specific lever, and it's the one founders underrate. Every product claim needs substantiation, every supplier needs documentation, and every piece of marketing copy needs to survive an FTC read. A buyer discounts a brand whose growth was bought with claims it can't defend, because that risk transfers at close. Running your own claims review before a buyer runs theirs is one of the highest-leverage things you can do.

Three: margin that survives scale. Healthy gross margin matters, but a buyer cares whether it holds when the brand moves from a contract manufacturer to a scaled supply chain, and whether it leans on one hero SKU. A margin that depends on a single supplier or a fragile freight arrangement is worth less than a slightly lower margin that's rock solid, the same way durable contribution margin beats a flattering headline number.

Four: a category a strategic is actively chasing. Position matters more in wellness than almost anywhere, because the strategics are shopping by theme. Greens, peptides, gut health, hormone health, and women's health are hot lanes in 2026, funded by venture and hunted by acquirers. A brand that credibly owns one of those positions is a brand a strategic would rather buy than build. A me-too brand in a crowded lane, however well run, stays near the sector floor.

Five: financials that run without the founder. The quiet cap on a lot of supplement multiples is founder dependency. A brand where the founder is the face of every claim, the closer on every retailer, and the final word on formulation is hard to value, because the buyer can see the asset walking out at close. Clean, accrual-based books, twelve-plus months of contribution margin by channel, and a team that runs the business are what let you keep your leverage in the data room. That visibility is the same financial stack a brand needs to run well in the first place.

The runway to a
sellable wellness
brand.

If you intend to sell, the worst time to start engineering your multiple is the quarter before you go to market, because every shortcut shows up in the data room. The right runway is roughly 12 to 18 months, long enough to build retention, clean claims, and a defensible financial story that look like the natural state of the business rather than a pre-sale dress-up. Here's how that work tends to sequence.

A caveat worth stating plainly: not every brand should be engineered for a sale, and a business built only to flip tends to be brittle. The reason this runway works is that it builds a better company whether or not you ever sell. Stronger retention, clean claims, durable margin, and a brand that runs without its founder are good for the business regardless of an exit. If you do the 12 to 18 months and decide to keep operating, you've still ended up with a healthier, cash-generating brand.

The other thing this runway buys you is optionality. A brand that's retention-strong, compliant, and clean can credibly run a process with strategics, OTC specialists, and sponsors all at the table, which is exactly the competitive tension that moves a multiple. A brand attractive to only one type of buyer has no leverage. The work above doesn't just lift your number, it widens the room, and a wider room is what turns a fair price into a premium one.

The wellness multiple is never magic, and it's never random. It's a proxy for a handful of things a buyer can underwrite: replenishment, clean claims, durable margin, a category thesis a strategic wants, and a business that runs without its founder. The billion-dollar 2026 deals, Grüns and Breathe Right, attached to brands that delivered on those, which is why they cleared double digits. The sector average near 10.7x EBITDA is where the healthy middle lives, and below it is where the claims-shaky, founder-bound, single-SKU brands end up no matter how good the product is. Knowing which part of that distribution you're building toward, and building for the buyer most likely to want you, is the entire game. For the full picture of where the exits landed this year, the running 2026 consumer brand exits tracker keeps score, and the parallel food and beverage DTC deal flow shows the same buyers hunting an adjacent shelf.

If you're building a wellness or supplement brand toward a sale and want to know what an acquirer will actually pay, and what's quietly capping your multiple, that's exactly the buy-side work I've run, applied to your brand before a buyer applies it to you. The consumer commerce practice exists for this kind of pre-deal work, and the profitability teardown is a good place to see how the real numbers tend to diverge from the deck.

Questions from founders
building toward a
wellness exit.

What multiple do supplement brands sell for in 2026?

Who is buying wellness and supplement brands right now?

Why did Unilever buy Grüns and bid on Thorne?

Do supplements sell for higher multiples than other consumer brands?

What makes a supplement brand acquirable at a premium?